Compare · DFTX vs ISPR
DFTX vs ISPR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Ispire Technology Inc. (ISPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and ISPR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 55.4x ISPR ($83.2M).
- DFTX has been more active in the news (8 items in the past 4 weeks vs 1 for ISPR).
- DFTX has more recent analyst coverage (8 ratings vs 2 for ISPR).
- Company
- Definium Therapeutics Inc.
- Ispire Technology Inc.
- Price
- $32.12-6.23%
- $1.42+2.16%
- Market cap
- $4.60B
- $83.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 8
- 1
- Recent ratings
- 8
- 2
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest ISPR
- IKE Tech Launches IKE 2.0 to Bring Continuous Compliance to Regulated Products
- Ispire Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Ispire Technology Inc. Reports Fourth Quarter and Fiscal Year 2026 Financial Results
- SEC Form 10-K filed by Ispire Technology Inc.
- Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2026 Earnings Conference Call
- Ispire Technology Inc. Appoints Steven Przybyla as President
- Ispire Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Cox Brent was granted 53,555 shares, increasing direct ownership by 62% to 139,863 units (SEC Form 4)
- Director Burch Christopher Robert was granted 45,760 shares, increasing direct ownership by 59% to 122,944 units (SEC Form 4)